Lenalidomide: Targeted Anemia Therapy for Myelodysplastic Syndromes

Cancer Control - United States
doi 10.1177/107327480601304s02
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Practical Considerations in the Use of Lenalidomide Therapy for Myelodysplastic Syndromes

Cancer Control
MedicineOncologyHematology
2006English

Management of Cytopenias During Treatment With Lenalidomide in Patients With Myelodysplastic Syndromes

The Open Leukemia Journal
2010English

Impact of Lenalidomide Use Among Non-Transfusion Dependent Patients With Myelodysplastic Syndromes

American Journal of Hematology
Hematology
2018English

The Myelodysplastic Syndromes: Diagnosis, Prognosis and Therapy

Italian Journal of Medicine
Medicine
2013English

Lenalidomide Use in Myelodysplastic Syndromes: Insights Into the Biologic Mechanisms and Clinical Applications

Cancer
Cancer ResearchOncology
2017English

Myelodysplastic Syndromes

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2011English

A Calcium- And Calpain-Dependent Pathway Determines the Response to Lenalidomide in Myelodysplastic Syndromes

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2016English

Developments in the Treatment of Transfusion-Dependent Anemia in Patients With Myelodysplastic Syndromes: Epidemiology, Etiology, Genetics, and Targeted Therapies

Advances in Genomics and Genetics
2014English

Myelodysplastic Syndromes

Cancer
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy